Fig. 7From: Immune checkpoint inhibitors for multiple myeloma immunotherapyPrecision treatment. Existing research results targeting NK cell immune checkpoint therapy mainly include preclinical studies of anti-CD96 and anti-TIGIT and clinical studies of anti-KIR and anti-NKG—2A. And the antibodies targeting T-cell immune checkpoint inhibitors, predominantly related to CTLA-4, PD-1 and TIM-3Back to article page